New drug combo aims to boost stem cell harvest in myeloma patients
NCT ID NCT03246529
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether adding BL-8040 to standard G-CSF helps collect more stem cells for transplant in multiple myeloma patients. About 180 participants received either the combo or a placebo. The goal is to see if more patients can collect enough cells in fewer sessions, making the transplant process smoother.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BL-8040 (a drug to help release stem cells) plus G-CSF (a standard growth factor)
What this could lead to
If successful, this combination could make stem cell collection faster and more reliable for multiple myeloma patients needing a transplant.
What could go wrong
This is a late-stage trial, but results are not yet final. The drug may not improve collection enough to change standard care, and side effects from BL-8040 are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Central Hospital of Southern Pest National Institute of Hematology and Infectious Diseases
Budapest, 1097, Hungary
-
Div. Clinicizzata di Ematologia - Policlinico Vittorio Emanuele
Catania, 95124, Italy
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital University Ramon y Cajal
Madrid, 135250, Spain
-
Hospital de La Santa Creu I Sant Pau
Barcelona, 08041, Spain
-
Huntsman Cancer Institute in University of Utah
Salt Lake City, Utah, 84112, United States
-
Loyola University Medical Center
Chicago, Illinois, 60611, United States
-
MD Anderson Cancer Center
Houston Texas, Texas, 77030, United States
-
Mayo Clinic
Rochester, Minnesota, 55902, United States
-
Presidio Ospedaliero Morelli Viale Europa
Reggio Calabria, 89133, Italy
-
The Washington University School of Medicine
St Louis, Missouri, 63110, United States
-
UCLA Medical Center
Los Angeles, California, 167817, United States
-
University of Cincinnati
Cincinnati, Ohio, 45221, United States
-
University of Debrecen
Debrecen, 4032, Hungary
-
University of Florida
Gainesville, Florida, 100278, United States
-
University of Koln
Cologne, Koln, 50923, Germany
-
University of Maryland
Baltimore, Maryland, 21201, United States
-
University of Miami
Miami, Florida, 33136, United States